Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection-Scotland, 2012-2013

Clinical Microbiology and Infection

Volumn 22, Issue 1, 2016, Pages 87-93

  Rajendran, R ^a   Sherry, L ^a   Nile, C J ^a   Sherriff, A ^a   Johnson, E M ^b   Hanson, M F ^c   Williams, C ^d   Munro, C A ^e   Jones, B J ^f   Ramage, G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c NHS LOTHIAN   (United Kingdom)

^d UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antifungal; Biofilm; Candida albicans; Candida glabrata; Candidaemia; Catheters; Drug resistance

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGE; ARTICLE; BIOFILM; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CATHETER; CATHETER REMOVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICROBIAL BIOMASS; MORTALITY; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM; AGED; CANDIDEMIA; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCOTLAND; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SCOTLAND;

EID: 84959294256     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.09.018     Document Type: Article

References (25)

1. Mensa J., Pitart C., Marco F. Treatment of critically ill patients with candidemia. Int J Antimicrob Agents 2008, 32(Suppl. 2):S93-S97.
2. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
3. Kojic E.M., Darouiche R.O. Candida infections of medical devices. Clin Microbiol Rev 2004, 17:255-267.
4. Lynch A.S., Robertson G.T. Bacterial and fungal biofilm infections. Annu Rev Med 2008, 59:415-428.
5. Sardi J.C., Scorzoni L., Bernardi T., Fusco-Almeida A.M., Mendes Giannini M.J. Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 2013, 62(Pt 1):10-24.
6. Andes D.R., Safdar N., Baddley J.W., Playford G., Reboli A.C., Rex J.H., et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. Clin Infect Dis 2012, 54:1110-1122.
7. Cornely O.A., Bassetti M., Calandra T., Garbino J., Kullberg B.J., Lortholary O., et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clin Microbiol Infect 2012, 18(Suppl. 7):19-37.
8. Tumbarello M., Posteraro B., Trecarichi E.M., Fiori B., Rossi M., Porta R., et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007, 45:1843-1850.
9. Tumbarello M., Fiori B., Trecarichi E.M., Posteraro P., Losito A.R., De Luca A., et al. Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One 2012, 7:e33705.
10. Sherry L., Rajendran R., Lappin D.F., Borghi E., Perdoni F., Falleni M., et al. Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. BMC Microbiol 2014, 14:182.
11. Ramage G., Vande Walle K., Wickes B.L., Lopez-Ribot J.L. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001, 45:2475-2479.
12. Honraet K., Goetghebeur E., Nelis H.J. Comparison of three assays for the quantification of Candida biomass in suspension and CDC reactor grown biofilms. J Microbiol Methods 2005, 63:287-295.
13. Pierce C.G., Uppuluri P., Tristan A.R., Wormley F.L., Mowat E., Ramage G., et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc 2008, 3:1494-1500.
14. Swindell K., Lattif A.A., Chandra J., Mukherjee P.K., Ghannoum M.A. Parenteral lipid emulsion induces germination of Candida albicans and increases biofilm formation on medical catheter surfaces. J Infect Dis 2009, 200:473-480.
15. Odds F.C., Hanson M.F., Davidson A.D., et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007, 56(Pt 8):1066-1075.
16. Das I., Nightingale P., Patel M., Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: Experience in a tertiary referral center in the UK. Int J Infect Dis 2011, 15:e759-e763.
17. Parmeland L., Gazon M., Guerin C., Argaud L., Lehot J.J., Bastien O., et al. Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade. Med Mycol 2013, 51:33-37.
18. Arendrup M.C., Dzajic E., Jensen R.H., Johansen H.K., Kjaeldgaard P., Knudsen J.D., et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: Data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013, 19:E343-E353.
19. Dimopoulos G., Ntziora F., Rachiotis G., Armaganidis A., Falagas M.E. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: Differences in risk factors and outcome. Anesth Analg 2008, 106:523-529. table of contents.
20. Mermel L.A., Allon M., Bouza E., Craven D.E., Flynn P., O'Grady N.P., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45.
21. Koehler P., Tacke D., Cornely O.A. Our 2014 approach to candidaemia. Mycoses 2014, 57:581-583.
22. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., Serody J., Edwards J.E., et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995, 21:994-996.
23. Ruan S.Y., Huang Y.T., Chu C.C., Yu C.J., Hsueh P.R. Candida glabrata fungaemia in a tertiary centre in Taiwan: Antifungal susceptibility and outcomes. Int J Antimicrob Agents 2009, 34:236-239.
24. Walraven C.J., Lee S.A. Antifungal lock therapy. Antimicrob Agents Chemother 2013, 57:1-8.
25. Nucci M., Anaissie E., Betts R.F., Dupont B.F., Wu C., Buell D.N., et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: Analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010, 51:295-303.